Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM)...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology Vol. 14; no. 1; pp. 1 - 166
Main Authors:	Bitoun, Samuel, Henry, Julien, Vauloup-Fellous, Christelle, Dib, Nicolas, Belkhir, Rakiba, Mouna, Lina, Joly, Candie, Desjardins, Delphine, Bitu, Marie, Le Grand, Roger, Seror, Raphaèle, Roque Afonso, Anne-Marie, Mariette, Xavier
Format:	Journal Article
Language:	English
Published:	London BioMed Central Ltd 13-10-2021 BioMed Central BMC
Subjects:	Analysis Antibodies Cancer vaccines Coronaviruses COVID-19 COVID-19 vaccines Daratumumab Health aspects Immune response (humoral) Immunization Immunoglobulin G Letter to the Editor Leukemia Messenger RNA mRNA mRNA vaccines Multiple myeloma Neutralization Patients Response rates Risk factors SARS-COV-2 Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple myeloma (MM) patients (n = 27). Response was analyzed 1 month after the second dose of anti-SARS-CoV-2 BNT162b2 vaccine. Multiple myeloma patients showed diminished levels of Anti-Spike IgG levels compared to controls, but with a high proportion of patients achieving a humoral response (89% vs. 97% in controls). Neutralizing antibodies were present in 74% of patients versus 96% of controls. Patients under current daratumumab treatment had neutralizing activity of anti-SARS-CoV-2 antibodies. Multiple myeloma patients show diminished response to SARS-COV-2 vaccine but with still high response rate. The main potential risk factor of non-response to COVID-19 vaccine was uncontrolled disease under treatment. Keywords: Multiple myeloma, Daratumumab, SARS-COV-2, Vaccine, COVID-19, Neutralization
Bibliography:	SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 ObjectType-Commentary-2
ISSN:	1756-8722 1756-8722
DOI:	10.1186/s13045-021-01183-2